Hidradenitis suppurativa (HS) is a chronic skin disease that causes painful, tender nodules under the skin. New injectable biologics for HS may help people control their pain from the disease. In this video, learn how biologics work to treat HS, according to Erum Ilyas, MD, Dermatologist with Montgomery Dermatology in Pennsylvania.
Erum Ilyas, MD, is a Dermatologist and founder of Montgomery Dermatology, which merged with Schweiger Dermatology, in Pennsylvania.
References
Ballard, K., et al. (2023). Hidradenitis suppurativa. StatPearls.
Bechara, F. G., et al. (2021). Efficacy and safety of adalimumab in conjunction with surgery in moderate to severe hidradenitis suppurativa. JAMA Surgery.
Joszt, L. (2023). Secukinumab gains FDA approval to treat hidradenitis suppurativa. American Journal of Managed Care.
Ludmann, P. (2022). Hidradenitis suppurativa: Overview. American Academy of Dermatology Association.
MedlinePlus. (2023). Hidradenitis suppurativa.
National Institute of Arthritis and Musculoskeletal and Skin Diseases. (2022). Hidradenitis suppurativa (HS).
National Institute of Arthritis and Musculoskeletal and Skin Diseases. (2022). Hidradenitis suppurativa (HS): Diagnosis, treatment, and steps to take.
U.S. Food and Drug Administration. (2018). HUMIRA (adalimumab) injection, for subcutaneous use [package insert].
U.S. Food and Drug Administration. (2023). COSENTYX (secukinumab) injection, for subcutaneous or intravenous use [package insert].
Why trust our experts?
